Thomas J. Garrity is Director at ANTARES PHARMA, INC. (ATRS). They have made 13 open-market trades across 2 companies since 2011, most recently 2022-05-24.
CIK 0001275012
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $47K since 2011, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ATRS | SELL | 2021-03-11 | 2021-03-12 | $4.28 | $214K | -10.9% | -9.4% | -1.6% |
| ATRS | SELL | 2021-02-11 | 2021-02-12 | $4.62 | $231K | -1.8% | -4.0% | -16.3% |
| ATRS | SELL | 2021-01-11 | 2021-01-13 | $4.06 | $284K | +7.1% | +6.8% | -4.7% |
| ATRS | SELL | 2019-12-09 | 2019-12-11 | $4.58 | $183K | +0.4% | -6.3% | -34.5% |
| ATRS | SELL | 2019-12-09 | 2019-12-11 | $4.58 | $183K | +0.4% | -6.3% | -34.5% |
| ATRS | SELL | 2019-05-01 | 2019-05-03 | $2.67 | $80K | -4.3% | -6.7% | +6.0% |
| ATRS | SELL | 2017-10-03 | 2017-10-05 | $3.50 | $105K | -44.3% | -49.6% | -40.8% |
| ATRS | SELL | 2017-03-31 | 2017-04-04 | $2.91 | $87K | -5.7% | +1.0% | +6.3% |
| ATRS | BUY | 2016-03-18 | 2016-03-21 | $0.72 | $22K | +10.9% | +8.3% | +25.6% |
| ATRS | BUY | 2014-08-11 | 2014-08-13 | $1.98 | $10K | -22.0% | -2.5% | -2.5% |
| ATRS | SELL | 2013-05-31 | 2013-06-03 | $4.08 | $53K | -22.0% | -2.5% | -2.5% |
| ATRS | SELL | 2012-08-20 | 2012-08-22 | $4.02 | $125K | -22.0% | -2.5% | -2.5% |
| AIS | BUY | 2011-03-18 | 2011-03-21 | $1.60 | $16K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.